Citius Oncology (CTOR) Projected to Post Earnings on Tuesday

Citius Oncology (NASDAQ:CTOR) is expected to announce its Q3 2026 results before the market opens on Tuesday, August 18th. Analysts expect the company to post earnings of ($0.04) per share and revenue of $5.8310 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

Citius Oncology (NASDAQ:CTOR) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.26). The business had revenue of $1.67 million during the quarter, compared to analyst estimates of $7.00 million.

Citius Oncology Price Performance

Shares of NASDAQ CTOR opened at $0.74 on Tuesday. The stock has a market capitalization of $68.57 million, a price-to-earnings ratio of -1.57 and a beta of 3.48. Citius Oncology has a 12 month low of $0.49 and a 12 month high of $2.25. The firm’s 50 day simple moving average is $0.68 and its 200-day simple moving average is $0.83. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.50 and a quick ratio of 0.12.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Citius Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $6.00.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CTOR. Geode Capital Management LLC lifted its position in shares of Citius Oncology by 179.0% during the 2nd quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock valued at $249,000 after buying an additional 36,758 shares in the last quarter. Jane Street Group LLC acquired a new stake in Citius Oncology in the 2nd quarter valued at $465,000. Bank of America Corp DE increased its holdings in Citius Oncology by 5,256.9% in the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after acquiring an additional 8,411 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Citius Oncology in the 3rd quarter worth $36,000. Finally, Armistice Capital LLC acquired a new position in Citius Oncology during the third quarter worth $15,582,000. 70.52% of the stock is owned by institutional investors and hedge funds.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.